Department of Pathology, Chi-Mei Foundational Medical Center, Tainan, Taiwan.
BMC Cancer. 2012 Dec 21;12:611. doi: 10.1186/1471-2407-12-611.
HuR is an RNA-binding protein that post-transcriptionally modulates the expressions of various target genes implicated in carcinogenesis, such as CCNA2 encoding cyclin A. No prior study attempted to evaluate the significance of HuR expression in a large cohort with upper urinary tract urothelial carcinomas (UTUCs).
In total, 340 cases of primary localized UTUC without previous or concordant bladder carcinoma were selected. All of these patients received ureterectomy or radical nephroureterectomy with curative intents. Pathological slides were reviewed, and clinical findings were collected. Immunostaining for HuR and cyclin A was performed and evaluated by using H-score. The results of cytoplasmic HuR and nuclear cyclin A expressions were correlated with disease-specific survival (DSS), metastasis-free survival (MeFS), urinary bladder recurrence-free survival (UBRFS), and various clinicopathological factors.
HuR cytoplasmic expression was significantly related to the pT status, lymph node metastasis, a higher histological grade, the pattern of invasion, vascular and perineurial invasion, and cyclin A expression (p = 0.005). Importantly, HuR cytoplasmic expression was strongly associated with a worse DSS (p < 0.0001), MeFS (p < 0.0001), and UBRFS (p = 0.0370) in the univariate analysis, and the first two results remained independently predictive of adverse outcomes (p = 0.038, relative risk [RR] = 1.996 for DSS; p = 0.027, RR = 1.880 for MeFS). Cyclin A nuclear expression was associated with a poor DSS (p = 0.0035) and MeFS (p = 0.0015) in the univariate analysis but was not prognosticatory in the multivariate analyses. High-risk patients (pT3 or pT4 with/without nodal metastasis) with high HuR cytoplasmic expression had better DSS if adjuvant chemotherapy was performed (p = 0.015).
HuR cytoplasmic expression was correlated with adverse phenotypes and cyclin A overexpression and also independently predictive of worse DSS and MeFS, suggesting its roles in tumorigenesis or carcinogenesis and potentiality as a prognostic marker of UTUC. High HuR cytoplasmic expression might identify patients more likely to be beneficial for adjuvant chemotherapy.
HuR 是一种 RNA 结合蛋白,可在后转录水平调节各种靶基因的表达,这些靶基因涉及致癌作用,如编码细胞周期蛋白 A 的 CCNA2。之前没有研究尝试在一个包含大量上尿路上皮尿路上皮癌 (UTUC) 的队列中评估 HuR 表达的意义。
共选择 340 例无既往或同时膀胱癌的原发性局部 UTUC 患者。所有患者均接受输尿管切除术或根治性肾输尿管切除术以达到治愈目的。对病理切片进行复查,并收集临床资料。采用免疫组织化学法检测 HuR 和细胞周期蛋白 A 的表达,并采用 H 评分进行评估。细胞质 HuR 和核细胞周期蛋白 A 表达的结果与疾病特异性生存率 (DSS)、无转移生存率 (MeFS)、无膀胱癌复发生存率 (UBRFS) 和各种临床病理因素相关。
细胞质 HuR 表达与 pT 分期、淋巴结转移、高级别组织学分级、浸润模式、血管和神经周围侵犯以及细胞周期蛋白 A 表达显著相关 (p=0.005)。重要的是,细胞质 HuR 表达在单因素分析中与较差的 DSS (p<0.0001)、MeFS (p<0.0001) 和 UBRFS (p=0.0370) 密切相关,前两个结果仍然独立预测不良预后 (p=0.038,相对风险 [RR] 为 1.996,用于 DSS;p=0.027,RR 为 1.880,用于 MeFS)。核细胞周期蛋白 A 表达在单因素分析中与较差的 DSS (p=0.0035) 和 MeFS (p=0.0015) 相关,但在多因素分析中无预后意义。接受辅助化疗的高风险患者 (有/无淋巴结转移的 pT3 或 pT4) 若细胞质 HuR 高表达,其 DSS 更好 (p=0.015)。
细胞质 HuR 表达与不良表型和细胞周期蛋白 A 过表达相关,且独立预测较差的 DSS 和 MeFS,提示其在肿瘤发生或致癌作用中的作用以及作为 UTUC 预后标志物的潜力。细胞质 HuR 高表达可能有助于识别更可能受益于辅助化疗的患者。